drugset / Trial / NCT04208581

Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure

NCT04208581

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to establish the treatment scheme of Yiqi Huoxue Huatan granule for chronic obstructive pulmonary disease (COPD) with chronic respiratory failure (CRF), reducing mortality, improving quality of life and forming high quality evidence.

Timeline

Start
2019-10-08
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Yiqi Huoxue Huatan granule Traditional medicine (herbal / TCM)
Background Budesonide Small molecule 320 ug Inhaled
Background Fluticasone Other / unclassified 250 ug Inhaled
Background Formoterol Other / unclassified 4.5 ug Inhaled
Background Salmeterol Other / unclassified 50 ug Inhaled
Background Tiotropium Other / unclassified 18 ug Inhaled